Participate in a Clinical Trial

Australian Alzheimer’s Research FOUNDATION is currently seeking participants for the following trials:

Study NAME AND WHO IS ELIGIBLE

THE SCHEDULE

Australian Alzheimer’s Research Foundation – TotAL Study Phase 2

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

Males aged 60 to 80 years of age inclusive, at the time of informed consent

The Aware study is evaluating an investigational medication (ABBV-8E12) that targets protein called tau, which builds-up in the brains of people with Early Alzheimer’s disease. This study will help determine if the investigational medication is safe and effective at slowing the progression of Early Alzheimer’s disease.

Who can be involved:

Male or female and age is between 55 and 85 years, at the time of informed consent

Must be diagnosed with mild cognitive impairment or mild Alzheimer’s disease

Has an identified, reliable, study partner (e.g. family member)

If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 12 weeks prior to randomization

This study will assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. Xanamem has been developed in response to evidence that there is a strong association between chronically raised cortisol levels in the blood and in the brain, and the development of Alzheimer’s disease.

Who can be involved:

Male or female, aged 50 to 85 years old inclusive, at the time of informed consent

Has an identified, reliable, study partner (e.g., family member)

Must be diagnosed with mild Alzheimer’s disease

If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 12 weeks prior to randomization

To evaluate the efficacy and safety of elenbecestat (E2609) on participant’s with early Alzheimer’s disease (including mild cognitive impairment due to Alzheimer’s and a subset of very mild Alzheimer’s disease dementia).

Who can be involved:

Male or female, aged 50 to 85 years old inclusive, at the time of informed consent

Has an identified, reliable, study partner (who spends 8+ hours a week with the subject)

Must have mild cognitive impairment due to Alzheimer’s disease or diagnosed with Alzheimer’s disease

To test whether two investigational drugs called CAD106 and CNP250, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer’s disease in participants at risk to develop clinical symptoms based on their age and genotype.

Who can be involved:

Male or female, aged 60 to 75 years of age inclusive, at the time of informed consent

Does not have a current medical or neurological condition that might impact cognition or performance on cognitive assessments